Cancer Health equity Equity Diversity and Inclusion LGBTQ Disparities
Cancer impacts people from lesbian, gay, bisexual, transgender, and queer communities differently from other people – and there’s still a long way to go to understand those differences.
Community Equity Diversity and Inclusion
Jamie L. Studts, PhD, co-leader of the University of Colorado Cancer Center’s Cancer Prevention and Control Program, has devoted much of his research career to studying inequities in lung cancer risk factors, screening, treatment, and survivorship.
Press Releases Equity Diversity and Inclusion Leadership
The University of Colorado Cancer Center is doubling down on its diversity, equity, inclusion, and access (DEIA) efforts in 2023, adding an associate director and deputy associate director of DEIA to its leadership team.
Research Community Equity Diversity and Inclusion
Whether they are focused on middle school and high school students, college undergraduates, or current medical students, pipeline programs at the University of Colorado Cancer Center are designed to expose students of all ages and backgrounds to the world of cancer science and research, with a special focus on giving students from underrepresented backgrounds the opportunity to see themselves working in the field.
Community Equity Diversity and Inclusion
About one in five people worldwide will develop cancer in their lifetimes and in 2020, the most recent year for which data are available, cancer accounted for nearly 10 million deaths worldwide.
Community Cancer Magazine Equity Diversity and Inclusion ColoradoSPH at CU Anschutz Leadership
Two important numbers to keep in mind are that 50.5% of the U.S. population is female, and that cancer will account for more than 606,000 deaths in the United States this year, making it the second-leading cause of death.
Research Education Community Equity Diversity and Inclusion
Xander Bradeen began his undergraduate studies at the University of Colorado Boulder planning to major in neuroscience as a pre-med student, the first in his family to pursue a college education. Then he learned about prairie voles.
Equity Diversity and Inclusion ColoradoSPH at CU Anschutz
April has been designated National Minority Cancer Awareness Month to bring attention to the health disparities that lead to higher rates of cancer in Black, Hispanic, American Indian/Alaskan Native, and other communities of color.
Research Community Faculty Equity Diversity and Inclusion ColoradoSPH at CU Anschutz
While conducting research for her doctoral dissertation, Channing Tate, PhD, MPH, spoke with 144 older Black adults about hospice care – what they knew about it, whether they’d consider it, what their experiences with hospice had been.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Mark Harden
